Vincent Lo Re1,2,3, Dena M Carbonari2,3, Kimberly A Forde2,3,4, David Goldberg2,3,4, James D Lewis2,3,4, Kevin Haynes2,3, Kimberly B F Leidl2, Rajender K Reddy4, Jason Roy2,3, Daohang Sha2, Amy R Marks5, Jennifer L Schneider5, Brian L Strom2,3,6, Douglas A Corley5. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 6. Rutgers Biomedical & Health Sciences, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Abstract
PURPOSE: Identification of acute liver failure (ALF) is important for post-marketing surveillance of medications, but the validity of using ICD-9 diagnoses and laboratory data to identify these events within electronic health records is unknown. We examined positive predictive values (PPVs) of hospital ICD-9 diagnoses and laboratory tests of liver dysfunction for identifying ALF within a large, community-based integrated care organization. METHODS: We identified Kaiser Permanente Northern California health plan members (2004-2010) with a hospital diagnosis suggesting ALF (ICD-9 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) plus an inpatient international normalized ratio ≥1.5 (off warfarin) and total bilirubin ≥5.0 mg/dL. Hospital records were reviewed by hepatologists to adjudicate ALF events. PPVs for confirmed outcomes were determined for individual ICD-9 diagnoses, diagnoses plus prescriptions for hepatic encephalopathy treatment, and combinations of diagnoses in the setting of coagulopathy and hyperbilirubinemia. RESULTS: Among 669 members with no pre-existing liver disease, chart review confirmed ALF in 62 (9%). Despite the presence of co-existing coagulopathy and hyperbilirubinemia, individual ICD-9 diagnoses had low PPVs (range, 5-15%); requiring prescriptions for encephalopathy treatment did not increase PPVs of these diagnoses (range, 2-23%). Hospital diagnoses of other liver disorders (ICD-9 573.8) plus hepatic coma (ICD-9 572.2) had high PPV (67%; 95%CI, 9-99%) but only identified two (3%) ALF events. CONCLUSIONS: Algorithms comprising relevant hospital diagnoses, laboratory evidence of liver dysfunction, and prescriptions for hepatic encephalopathy treatment had low PPVs for confirmed ALF events. Studies of ALF will need to rely on medical records to confirm this outcome.
PURPOSE: Identification of acute liver failure (ALF) is important for post-marketing surveillance of medications, but the validity of using ICD-9 diagnoses and laboratory data to identify these events within electronic health records is unknown. We examined positive predictive values (PPVs) of hospital ICD-9 diagnoses and laboratory tests of liver dysfunction for identifying ALF within a large, community-based integrated care organization. METHODS: We identified Kaiser Permanente Northern California health plan members (2004-2010) with a hospital diagnosis suggesting ALF (ICD-9 570, 572.2, 572.4, 572.8, 573.3, 573.8, or V42.7) plus an inpatient international normalized ratio ≥1.5 (off warfarin) and total bilirubin ≥5.0 mg/dL. Hospital records were reviewed by hepatologists to adjudicate ALF events. PPVs for confirmed outcomes were determined for individual ICD-9 diagnoses, diagnoses plus prescriptions for hepatic encephalopathy treatment, and combinations of diagnoses in the setting of coagulopathy and hyperbilirubinemia. RESULTS: Among 669 members with no pre-existing liver disease, chart review confirmed ALF in 62 (9%). Despite the presence of co-existing coagulopathy and hyperbilirubinemia, individual ICD-9 diagnoses had low PPVs (range, 5-15%); requiring prescriptions for encephalopathy treatment did not increase PPVs of these diagnoses (range, 2-23%). Hospital diagnoses of other liver disorders (ICD-9 573.8) plus hepatic coma (ICD-9 572.2) had high PPV (67%; 95%CI, 9-99%) but only identified two (3%) ALF events. CONCLUSIONS: Algorithms comprising relevant hospital diagnoses, laboratory evidence of liver dysfunction, and prescriptions for hepatic encephalopathy treatment had low PPVs for confirmed ALF events. Studies of ALF will need to rely on medical records to confirm this outcome.
Authors: George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee Journal: Ann Intern Med Date: 2002-12-17 Impact factor: 25.391
Authors: Vincent Lo Re; Kevin Haynes; David Goldberg; Kimberly A Forde; Dena M Carbonari; Kimberly B F Leidl; Sean Hennessy; K Rajender Reddy; Pamala A Pawloski; Gregory W Daniel; T Craig Cheetham; Aarthi Iyer; Kara O Coughlin; Sengwee Toh; Denise M Boudreau; Nandini Selvam; William O Cooper; Mano S Selvan; Jeffrey J VanWormer; Mark I Avigan; Monika Houstoun; Gwen L Zornberg; Judith A Racoosin; Azadeh Shoaibi Journal: Pharmacoepidemiol Drug Saf Date: 2013-06-25 Impact factor: 2.890
Authors: Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon Journal: Gastroenterology Date: 2008-09-17 Impact factor: 22.682
Authors: K Arnold Chan; Alison Truman; Jerry H Gurwitz; Judith S Hurley; Brian Martinson; Richard Platt; James E Everhart; Richard H Moseley; Norah Terrault; Lynn Ackerson; Joe V Selby Journal: Arch Intern Med Date: 2003-03-24
Authors: Vincent Lo Re; Kevin Haynes; Kimberly A Forde; David S Goldberg; James D Lewis; Dena M Carbonari; Kimberly B F Leidl; K Rajender Reddy; Melissa S Nezamzadeh; Jason Roy; Daohang Sha; Amy R Marks; Jolanda De Boer; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Clin Gastroenterol Hepatol Date: 2015-06-27 Impact factor: 11.382
Authors: Vincent Lo Re; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Kevin Haynes; Jason A Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley Journal: Am J Med Date: 2015-11-17 Impact factor: 4.965
Authors: Charitha Gowda; Craig W Newcomb; Qing Liu; Dena M Carbonari; James D Lewis; Kimberly A Forde; David S Goldberg; K Rajender Reddy; Jason A Roy; Amy R Marks; Jennifer L Schneider; Jay R Kostman; Janet P Tate; Joseph K Lim; Amy C Justice; Matthew Bidwell Goetz; Douglas A Corley; Vincent Lo Re Journal: Open Forum Infect Dis Date: 2017-01-28 Impact factor: 3.835
Authors: Manel Pladevall-Vila; Anton Pottegård; Tania Schink; Johan Reutfors; Rosa Morros; Beatriz Poblador-Plou; Antje Timmer; Joan Forns; Maja Hellfritzsch; Tammo Reinders; David Hägg; Maria Giner-Soriano; Alexandra Prados-Torres; Miguel Cainzos-Achirica; Jesper Hallas; Lena Brandt; Jordi Cortés; Jaume Aguado; Gabriel Perlemuter; Bruno Falissard; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann Journal: CNS Drugs Date: 2019-04 Impact factor: 5.749